The Bioequivalence of Doxazosin Slow Release Tablets: A Pilot Study

The Bioequivalence of Doxazosin Slow Release Tablets: A Pilot Study


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

₹ 5,066

Availability: Out of stock


Delivery :

5% Cashback on all Orders paid using MobiKwik Wallet T&C

Free Krispy Kreme Voucher on all Orders paid using UltraCash Wallet T&C
Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description

Generic drugs used instead of originator products have to undergo obligatory bioequivalence studies before being approved on the market. The study was designed to validate a chromatographic and extraction method for the determination of doxazosin in human plasma and to carry out a pilot study on the bioequivalence between the test product, doxazosin mesylate 8mg slow release tablets and the reference product, Cardura®XL 8mg tablets. The study was determined in two healthy individuals after one single dose in a cross over study with a two week wash out period. A simple and sensitive liquid-liquid extraction method was validated for the quantification of doxazosin in human plasma using reversed-phase high performance liquid chromatography with fluorescence detection. The bioequivalence study showed significant variance between the generic and reference product and although further studies using larger number of individuals is recommended, such pilot studies gives an indication on the systemic exposure pattern and are beneficial to manufacturers as indicators of their products’ performance in vivo before embarking on full scale bioequivalence trials.

Product Specifications
SKU :COC84917
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-10-08
0 Review(s)